Virtu Financial’s Kalaris Therapeutics KLRS Stock Holding History

Virtu Financial’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44K	Buy	+10,845	New	+$56.3K	﹤0.01%	1236
2025 Q1	–	Sell	-2,025	Closed	-$20K	–	2196
2024 Q4	$20K	Buy	+2,025	New	+$30.6K	﹤0.01%	1305
2024 Q1	–	Sell	-1,794	Closed	-$28K	–	2231
2023 Q4	$28K	Buy	+1,794	New	+$70.7K	﹤0.01%	1268
2023 Q3	–	Sell	-594	Closed	-$46K	–	2016
2023 Q2	$46K	Buy	+594	New	+$56.5K	﹤0.01%	1152
2022 Q3	–	Sell	-614	Closed	-$55K	–	2330
2022 Q2	$55K	Buy	+614	New	+$64.4K	﹤0.01%	1099

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's KLRS Position: Q2 2026 in Review

Virtu Financial opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 10,845 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #1236 among its holdings. This is a return to the name: Virtu Financial previously reported a position in KLRS as recently as Q4 2024.

Virtu Financial first reported a position in KLRS in Q2 2022 and has held it in 5 quarters since. The position peaked at $55K in Q2 2022. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

Virtu Financial held 10,845 shares of Kalaris Therapeutics worth $44K as of Q2 2026.
Kalaris Therapeutics was a new Virtu Financial position in Q2 2026.
Kalaris Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1236 holding.
Virtu Financial first reported a position in Kalaris Therapeutics in Q2 2022 and has held it in 5 quarters since.
Virtu Financial's Kalaris Therapeutics position peaked at $55K in Q2 2022.
57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.